No Data
No Data
Strong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive Outlook
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
Express News | JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32
No Data